Teva Pharmaceutical Industries Limited (TLV: TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
7,712.00
+142.00 (1.88%)
Dec 19, 2024, 5:24 PM IDT
103.00%
Market Cap 91.39B
Revenue (ttm) 62.35B
Net Income (ttm) -3.56B
Shares Out n/a
EPS (ttm) -3.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,829,928
Open 7,600.00
Previous Close 7,570.00
Day's Range 7,593.00 - 7,845.00
52-Week Range 3,750.00 - 7,845.00
Beta 0.88
Analysts n/a
Price Target n/a
Earnings Date Jan 29, 2025

About TLV: TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. ... [Read more]

Sector Healthcare
Founded 1901
Employees 36,472
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2023, TEVA's revenue was $15.85 billion, an increase of 6.17% compared to the previous year's $14.93 billion. Losses were -$559.00 million, -77.15% less than in 2022.

Financial numbers in USD Financial Statements

News

Teva Pharmaceutical Industries Ltd (TEVA) Announces Upcoming Financial Results Release and ...

Teva Pharmaceutical Industries Ltd (TEVA) Announces Upcoming Financial Results Release and Conference Call

1 day ago - GuruFocus

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) --  Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 20...

1 day ago - GlobeNewsWire

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. ... Full story available on Benzinga.co...

3 days ago - Benzinga

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

Teva Pharmaceutical Industries Ltd.  TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).

3 days ago - Benzinga

Sanofi and Teva Achieve Milestone in Ulcerative Colitis Treatment Study

Sanofi and Teva Achieve Milestone in Ulcerative Colitis Treatment Study

3 days ago - GuruFocus

TEVA stock soars 26%: What's going on with Teva Pharmaceuticals?

Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced groundbreaking results from clinical trials of their drug, duvakitug, for ulcerative colitis and Crohn's disease...

4 days ago - Invezz

Nukkleus, Micron, Teva Pharmaceutical, Quantum Computing, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Wall Street experienced a downturn on Tuesday as major indices fell following a strong retail sales report for November. The data raised concerns about the Federal Reserve’s potential delay in cutting...

4 days ago - Benzinga

Overlooked Stock: TEVA

Teva Pharmaceutical (TEVA) closed at its highest stock price of the year after it and Sanofi (SNY) say their IBD treatment had higher remission in trial. George Tsilis looks at how the development can...

4 days ago - Schwab Network

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's

Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease.

4 days ago - Investopedia

Stocks making the biggest moves midday: Pfizer, Broadcom, Teva Pharmaceuticals and more

These are the stocks posting the largest moves in midday trading.

4 days ago - CNBC

Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations

Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations

4 days ago - GuruFocus

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.

4 days ago - WSJ

Teva Pharmaceuticals (TEVA) Shares Surge Over 15% on Positive Drug Study Results

Teva Pharmaceuticals (TEVA) Shares Surge Over 15% on Positive Drug Study Results

4 days ago - GuruFocus

RCI Hospitality, Quantum Computing, Teva Pharmaceutical, Tesla And Other Big Stocks Moving Higher On Monday

U.S. stocks were mostly higher, with the Nasdaq Composite gaining around 1% on Monday. Shares of RCI Hospitality Holdings, Inc . (NASDAQ: RICK) rose sharply during Tuesday's session after the company...

4 days ago - Benzinga

Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug

Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study.

4 days ago - Investor's Business Daily

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

Teva and Sanofi's Phase 2b RELIEVE ... Full story available on Benzinga.com

4 days ago - Benzinga

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).

4 days ago - Benzinga

Teva, Sanofi gain after mid-stage trial win for IBD therapy

Teva (TEVA) stock and Sanofi (SNY) stock jump after a mid-stage trial win for an experimental antibody therapy targeting inflammatory bowel diseases. Read more here.

5 days ago - Seeking Alpha

Teva Pharmaceutical Industries Ltd (TEVA) Announces Positive Phase 2b Study Results for ...

Teva Pharmaceutical Industries Ltd (TEVA) Announces Positive Phase 2b Study Results for Duvakitug in Treating Inflammatory Bowel Disease

5 days ago - GuruFocus

Teva, Sanofi say drug to treat IBD met primary targets

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.

5 days ago - Reuters

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most co...

5 days ago - Benzinga

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease

Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the h...

5 days ago - Benzinga

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease

Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the h...

5 days ago - GlobeNewsWire

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ: FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024...

8 days ago - Benzinga

Teva Pharmaceutical Industries Ltd (TEVA) Launches Inhaler Donation Program for Uninsured Patients

Teva Pharmaceutical Industries Ltd (TEVA) Launches Inhaler Donation Program for Uninsured Patients

11 days ago - GuruFocus